Literature DB >> 24046013

High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis.

Daniel Fürst1, Carlheinz Müller, Vladan Vucinic, Donald Bunjes, Wolfgang Herr, Martin Gramatzki, Rainer Schwerdtfeger, Renate Arnold, Hermann Einsele, Gerald Wulf, Michael Pfreundschuh, Bertram Glass, Hubert Schrezenmeier, Klaus Schwarz, Joannis Mytilineos.   

Abstract

To validate current donor selection strategies based on previous international studies, we retrospectively analyzed 2646 transplantations performed for hematologic malignancies in 28 German transplant centers. Donors and recipients were high resolution typed for HLA-A, -B, -C, -DRB1, and -DQB1. The highest mortality in overall survival analysis was seen for HLA-A, -B, and DRB1 mismatches. HLA-DQB1 mismatched cases showed a trend toward higher mortality, mostly due to HLA-DQB1 antigen disparities. HLA incompatibilities at >1 locus showed additive detrimental effects. HLA mismatching had no significant effect on relapse incidence and primary graft failure. Graft source had no impact on survival end points, neither in univariate nor in multivariate analysis. Higher patient age, advanced disease, transplantations before 2004, patient C2C2 killer cell immunoglobulin-like receptor (KIR)-ligand phenotype, and unavailability of a national donor adversely influenced outcomes in multivariate analysis. Our study confirms the association of HLA-A, -B, -C, and -DRB1 incompatibilities with adverse outcome in hematopoietic stem cell transplantation (HSCT). The relevance of HLA-DQB1 disparities in single mismatched transplantations remains unclear. Similar hazard ratios for allele and antigen mismatches (possibly with an exception for HLA-DQB1) highlight the importance of allele level typing and matching in HSCT. The number of incompatibilities and their type significantly impact survival.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24046013     DOI: 10.1182/blood-2013-02-482547

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

Review 1.  Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection.

Authors:  Katharina Fleischhauer; Katharine C Hsu; Bronwen E Shaw
Journal:  Bone Marrow Transplant       Date:  2018-05-24       Impact factor: 5.483

2.  Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation.

Authors:  Marcelo A Fernandez-Viña; Tao Wang; Stephanie J Lee; Michael Haagenson; Mahmoud Aljurf; Medhat Askar; Minoo Battiwalla; Lee-Ann Baxter-Lowe; James Gajewski; Ann A Jakubowski; Susana Marino; Machteld Oudshoorn; Steven G E Marsh; Effie W Petersdorf; Kirk Schultz; E Victoria Turner; Edmund K Waller; Ann Woolfrey; John Umejiego; Stephen R Spellman; Michelle Setterholm
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

3.  Limited HLA sequence variation outside of antigen recognition domain exons of 360 10 of 10 matched unrelated hematopoietic stem cell transplant donor-recipient pairs.

Authors:  L Hou; C Vierra-Green; A Lazaro; C Brady; M Haagenson; S Spellman; C K Hurley
Journal:  HLA       Date:  2016-12-15       Impact factor: 4.513

4.  Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation.

Authors:  B E Shaw; F Lee; S Krishnamurthy; J L Byrne; C Seedhouse; N P Mayor; H Maldonado-Torres; A Saudemont; S G E Marsh; J A Madrigal; N H Russell
Journal:  Bone Marrow Transplant       Date:  2014-10-27       Impact factor: 5.483

5.  Physiochemical disparity of mismatched HLA class I alloantigens and risk of acute GVHD following HSCT.

Authors:  V Kosmoliaptsis; M M Jöris; D H Mallon; A C Lankester; P A von dem Borne; J Kuball; M Bierings; J J Cornelissen; M E Groenendijk-Sijnke; B van der Holt; J A Bradley; M Oudshoorn; J J van Rood; C J Taylor; F H J Claas
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

6.  HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.

Authors:  Michael A Spinner; Marcelo Fernández-Viña; Lisa E Creary; Olivia Quinn; Linda Elder; Sally Arai; Laura J Johnston; Everett H Meyer; David B Miklos; Lori S Muffly; Robert S Negrin; Judith A Shizuru; Wen-Kai Weng; Ginna G Laport; Samuel Strober; Robert Lowsky; Andrew R Rezvani
Journal:  Blood Adv       Date:  2017-07-25

7.  Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation.

Authors:  Daniel Fuerst; Carlheinz Mueller; Dietrich W Beelen; Christine Neuchel; Chrysanthi Tsamadou; Hubert Schrezenmeier; Joannis Mytilineos
Journal:  Haematologica       Date:  2015-11-26       Impact factor: 9.941

8.  Better allele-level matching improves transplant-related mortality after double cord blood transplantation.

Authors:  Betül Oran; Kai Cao; Rima M Saliba; Katayoun Rezvani; Marcos de Lima; Sairah Ahmed; Chitra M Hosing; Uday R Popat; Yudith Carmazzi; Partow Kebriaei; Yago Nieto; Gabriela Rondon; Dana Willis; Nina Shah; Simrit Parmar; Amanda Olson; Brandt Moore; David Marin; Rohtesh Mehta; Marcelo Fernández-Viña; Richard E Champlin; Elizabeth J Shpall
Journal:  Haematologica       Date:  2015-08-06       Impact factor: 9.941

9.  Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most.

Authors:  Bronwen E Shaw; Brent R Logan; Stephen R Spellman; Steven G E Marsh; James Robinson; Joseph Pidala; Carolyn Hurley; Juliet Barker; Martin Maiers; Jason Dehn; Hailin Wang; Mike Haagenson; David Porter; Effie W Petersdorf; Ann Woolfrey; Mary M Horowitz; Michael Verneris; Katharine C Hsu; Katharina Fleischhauer; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2018-02-14       Impact factor: 5.742

10.  HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.

Authors:  Loren Gragert; Mary Eapen; Eric Williams; John Freeman; Stephen Spellman; Robert Baitty; Robert Hartzman; J Douglas Rizzo; Mary Horowitz; Dennis Confer; Martin Maiers
Journal:  N Engl J Med       Date:  2014-07-24       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.